GlassScriptPhysician profile
Jaya Naran
NPI 1316394448
$3,102.59
in general payments reported to CMS, 2019-2025
27 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.86 · 2023: $1,203 · 2024: $985 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $434.55 | 2020-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $372.27 | 2023-2025 | Jardiance, Mounjaro, Baqsimi |
| Sanofi-Aventis U.S. LLC | $291.31 | 2023-2025 | |
| Abbott Laboratories | $276.17 | 2023-2025 | Freestyle Libre |
| Novo Nordisk INC | $243.28 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.32 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $150.49 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $124.83 | 2023-2025 | |
| Abbvie INC. | $120.52 | 2023-2025 | |
| Dexcom, INC. | $117.97 | 2024-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $102.02 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $98.79 | 2023-2024 | |
| Insulet Corporation | $88.75 | 2023-2025 | Omnipod |
| Pfizer INC. | $74.28 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $68.02 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $60.77 | 2023-2024 | |
| Averitas Pharma INC. | $50.77 | 2025 | Qutenza |
| Ibsa Pharma INC. | $48.93 | 2023-2024 | Tirosint, Licart, Tirosint |
| Medtronic, INC. | $45.95 | 2023 | Minimed 780g |
| Rgh Enterprises LLC | $40.08 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.57 | 2023 | Evkeeza, Praluent |
| Recordati_rare_diseases_inc. | $19.58 | 2024 | Signifor Lar, Isturisa |
| Neurocrine Biosciences, INC. | $18.58 | 2024 | Ingrezza |
| Horizon Therapeutics Plc | $17.08 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $16.94 | 2025 | Yorvipath |
| Corcept Therapeutics | $16.39 | 2023 | Korlym |
| Amneal Pharmaceuticals LLC | $13.38 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaya Naran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.